New HampshireNew Hampshire adopts an interstate licensing agreement for physician associates
New Hampshire’s law lets eligible physician associates seek permission to treat patients across participating states once at least seven states enact the licensing agreement.
What it does
New Hampshire adopts a licensing agreement for physician associates. Eligible providers may practice across participating states under local care rules, once at least seven states have enacted the agreement.
The law allows licensed physicians and qualified licensed practitioners to administer ibogaine under a Food and Drug Administration-approved research plan, if federal law allows.
Argument forRecognizing eligible physician associates’ licenses across participating states could help them serve more patients while remaining accountable to local licensing boards.
Argument againstThe agreement could add costs for physician associates through practice fees and for participating states through annual payments.
More detail
New Hampshire adopts an interstate licensing agreement for physician associates, also called physician assistants. Eligible physician associates may obtain permission to treat patients in other participating states. They must follow the laws where the patient is located. Applicants need an approved education, current national certification, and an unrestricted license from a participating state. Applicants must have no felony or misdemeanor conviction, no revoked PA license, and no suspended or revoked permission to handle controlled drugs. Current license restrictions from discipline bar eligibility. Past restrictions generally require a two-year wait after removal; states may disregard discipline for conduct that is lawful in their state. Applicants must notify the agreement’s commission and meet any required test on state laws. Fees may apply, and prescribing controlled drugs requires meeting the patient’s state requirements. The law took effect September 13, 2026. The agreement takes effect when the seventh state enacts it; states joining later must pass the commission’s review.
Licensed physicians and qualified licensed practitioners may administer ibogaine under an approved research plan. This permission covers licensed physicians and qualified licensed practitioners. The research plan must be approved by the Food and Drug Administration. Federal law must allow the administration. The ibogaine provision took effect September 13, 2026.
Where do you stand?
Choose your position
Tell your reps
Take a position to see your representatives and ways to contact them.
Where it stands
- Introduced
- Passed House
- Passed Senate
- To Governor
- Became Law
Looking ahead
No hearings or votes scheduled.
History
- 2026
- Jul 20Signed by Governor Kelly Ayotte Ayotte 07/15/2026; Chapter 333; eff. 09/13/2026Became Law
- Jul 6Enrolled Adopted, VV, (In recess 06/04/2026); SJ 15To Governor
- Jul 6Enrolled (in recess of) 06/04/2026 HJ 15 P. 56
- Jun 23Enrolled Bill Amendment # 2026-2184e: AA VV (in recess of) 06/04/2026 HJ 15 P. 53
- Jun 23Enrolled Bill Amendment # 2026-2184e Adopted, VV, (In recess of 06/04/2026); SJ 14Major
- Jun 4Conference Committee Report 2026-2090c: Adopted, VV 06/04/2026 HJ 15 P. 13
- Jun 4Conference Committee Report # 2026-2090c, Adopted, VV; 06/04/2026; SJ 14
- May 28Conference Committee Report Filed, # 2026-2090c; 06/04/2026
- May 27Conference Committee Meeting: 05/27/2026 01:45 pm GP 231
- May 20President Appoints: Senators Rochefort, Pearl, Prentiss; (In Recess 05/14/2026); SJ 13
- May 20Sen. Rochefort Accedes to House Request for Committee of Conference, MA, VV; (In recess 05/14/2026); SJ 13
- May 14Speaker Appoints: Reps. W. MacDonald, Drew, Markell, Milz 05/14/2026 HJ 13 P. 152
- May 14House Non-Concurs with Senate Amendment 2026-1916s and 2026-1623s and Requests CofC (Rep. W. MacDonald): MA VV 05/14/2026 HJ 13 P. 152
- May 14Ought to Pass with Amendments #2026-1623s and #2026-1916s, MA, VV; OT3rdg; 05/14/2026; SJ 12Passed Senate
- May 14Sen. Rochefort Floor Amendment # 2026-1916s, AA, VV; 05/14/2026; SJ 12
- May 14Committee Amendment # 2026-1623s, AA, VV; 05/14/2026; SJ 12
- May 7Committee Report: Ought to Pass with Amendment # 2026-1623s, 05/14/2026, Vote 4-0; SC 18Minor
- May 7Special Order to 05/14/2026, Without Objection, MA; 05/07/2026 SJ 11
- Apr 22Committee Report: Ought to Pass with Amendment # 2026-1623s, 05/07/2026, Vote 4-0; SC 17Minor
- Mar 24Hearing: 03/25/2026, Room 100, SH, 10:00 am; SC 12
- Mar 17Introduced 03/12/2026 and Referred to Health and Human Services; SJ 7Minor
- Mar 11Amendment # 2026-0365h: AA VV 03/11/2026 HJ 7 P. 206
- Mar 11Ought to Pass with Amendment 2026-0365h: MA DV 176-156 03/11/2026 HJ 7 P. 207Passed House
- Mar 4Minority Committee Report: Refer for Interim Study
- Mar 4Majority Committee Report: Ought to Pass with Amendment # 2026-0365h 03/04/2026 (Vote 10-8; RC) HC 10 P. 53Minor
- Feb 27Executive Session: 03/04/2026 09:00 am GP 158
- Feb 18Public Hearing: 02/24/2026 02:00 pm GP 158
- Feb 17==CANCELLED== Public Hearing: 02/23/2026 02:00 pm GP 158
- 2025
- Dec 17Introduced 01/07/2026 and referred to Health, Human Services and Elderly Affairs HJ 1 P. 35Introduced
Healthcare